Alnylam Pharmaceuticals Inc

Alnylam’s vutrisiran shows promising results for ATTR‑CM, boosting RNAi therapy prospects while a key leadership shift raises questions about its future pipeline strategy.

Alnylam partners with Viz.ai and the AHA to launch AI‑driven tools for early ATTR‑CM detection, boosting diagnosis, treatment timing and clinical outcomes.

Alnylam Pharmaceuticals sees rising short‑interest and insider sales while its amyloidosis drug and 2026 outlook spark cautious investor curiosity.

Alnylam Pharmaceuticals joins the Nasdaq 100, boosting liquidity, index‑fund exposure, and analyst confidence, while its RNA‑i pipeline and strategic buybacks signal growth in a $73B non‑opioid therapeutics market.

Alnylam’s Q3 earnings jump 149% with Amvuttra sales, up‑raised 2025 revenue guidance, and a strong 52‑week high – a biotech surge worth watching.

Alnylam Pharmaceuticals Inc. is revolutionizing the treatment of cardiovascular diseases with its innovative drugs Zilebesiran and AMVUTTRA, which are showing promising results in clinical trials and poised to transform the management of hypertensio…

Alnylam Pharmaceuticals Inc. is advancing its RNAi therapeutic zilebesiran into a global Phase 3 cardiovascular outcomes trial, building on promising results from the KARDIA Phase 2 program and positioning the company for a potential breakthrough in…

Alnylam Pharmaceuticals has delivered a strong financial performance, exceeding expectations and setting a new benchmark for its peers in the healthcare sector, solidifying its position as a leader in the biotechnology industry.

Alnylam Pharmaceuticals Inc. has made significant strides in recent developments, including EU approval of its transthyretin amyloidosis treatment and strong earnings expectations, positioning the company for continued growth and innovation.

Alnylam Pharmaceuticals Inc. has seen a robust stock performance, reaching a 52-week high, with analysts and experts expressing optimism about the company’s future growth prospects.